Article
Refine
Year of publication
- 2024 (5)
- 2023 (15)
- 2022 (14)
- 2021 (11)
- 2020 (10)
- 2019 (7)
- 2018 (12)
- 2017 (11)
- 2016 (19)
- 2015 (20)
- 2014 (25)
- 2013 (24)
- 2012 (15)
- 2011 (22)
- 2010 (16)
- 2009 (18)
- 2008 (10)
- 2007 (14)
- 2006 (13)
- 2005 (12)
- 2004 (8)
- 2003 (8)
- 2002 (15)
- 2001 (16)
- 2000 (9)
- 1999 (10)
- 1998 (23)
- 1997 (15)
- 1996 (8)
- 1995 (28)
- 1994 (22)
- 1993 (9)
- 1992 (20)
- 1991 (8)
- 1990 (14)
- 1989 (15)
- 1988 (13)
- 1987 (12)
- 1986 (10)
- 1985 (7)
- 1984 (7)
- 1983 (9)
- 1982 (3)
- 1981 (2)
- 1980 (3)
- 1979 (8)
- 1978 (2)
- 1976 (1)
- 1975 (3)
- 1972 (1)
- 1971 (2)
Institute
- Fachbereich Chemie und Biotechnologie (604) (remove)
Document Type
- Article (604) (remove)
Keywords
- Heparin (3)
- Bacillaceae (2)
- Biotechnological application (2)
- Butanol (2)
- Chemometrics (2)
- IR spectroscopy (2)
- NMR spectroscopy (2)
- Principal component analysis (2)
- Standardization (2)
- Subtilases (2)
The molecular events during nongenotoxic carcinogenesis and their temporal order are poorly understood but thought to include long-lasting perturbations of gene expression. Here, we have investigated the temporal sequence of molecular and pathological perturbations at early stages of phenobarbital (PB) mediated liver tumor promotion in vivo. Molecular profiling (mRNA, microRNA [miRNA], DNA methylation, and proteins) of mouse liver during 13 weeks of PB treatment revealed progressive increases in hepatic expression of long noncoding RNAs and miRNAs originating from the Dlk1-Dio3 imprinted gene cluster, a locus that has recently been associated with stem cell pluripotency in mice and various neoplasms in humans. PB induction of the Dlk1-Dio3 cluster noncoding RNA (ncRNA) Meg3 was localized to glutamine synthetase-positive hypertrophic perivenous hepatocytes, sug- gesting a role for β-catenin signaling in the dysregulation of Dlk1-Dio3 ncRNAs. The carcinogenic relevance of Dlk1-Dio3 locus ncRNA induction was further supported by in vivo genetic dependence on constitutive androstane receptor and β-catenin pathways. Our data identify Dlk1-Dio3 ncRNAs as novel candidate early biomarkers for mouse liver tumor promotion and provide new opportunities for assessing the carcinogenic potential of novel compounds.
1. Drug metabolizing enzymes and transporters play important roles in the absorption, metabolism, tissue distribution and excretion of various compounds and their metabolites and thus can significantly affect their efficacy and safety. Furthermore, they can be involved in drug–drug interactions which can result in adverse responses, life-threatening toxicity or impaired efficacy. Significant species differences in the interaction of compounds with drug metabolizing enzymes and transporters have been described.
2. In order to overcome the limitation of animal models in accurately predicting human responses, a large variety of mouse models humanized for drug metabolizing enzymes and to a lesser extent drug transporters have been created.
3. This review summarizes the literature describing these mouse models and their key applications in studying the role of drug metabolizing enzymes and transporters in drug bioavailability, tissue distribution, clearance and drug–drug interactions as well as in human metabolite testing and risk assessment.
4. Though such humanized mouse models have certain limitations, there is great potential for their use in basic research and for testing and development of new medicines. These limitations and future potentials will be discussed.